» Articles » PMID: 36643539

Surface Modification of Lipid-Based Nanocarriers: A Potential Approach to Enhance Targeted Drug Delivery

Overview
Journal ACS Omega
Specialty Chemistry
Date 2023 Jan 16
PMID 36643539
Authors
Affiliations
Soon will be listed here.
Abstract

Nanocarriers have the utmost significance for advancements in drug delivery and nanomedicine technology. They are classified as polymer-based nanocarriers, lipid-based nanocarriers, viral nanoparticles, or inorganic nanoparticles, depending on their constituent parts. Lipid-based nanocarrier systems have gained tremendous attention over the years because of their noteworthy properties like high drug-loading capacity, lower toxicity, better bioavailability and biocompatibility, stability in the gastrointestinal tract, controlled release, simpler scale-up, and validation process. Nanocarriers still have some disadvantages like poor drug penetration, limited drug encapsulation, and poor targeting. These disadvantages can be overcome by their surface modification. Surface-modified nanocarriers result in controlled release, enhanced penetration efficiency, and targeted medication delivery. In this review, the authors summarize the numerous lipid-based nanocarriers and their functionalization through various surface modifiers such as polymers, ligands, surfactants, and fatty acids. Recent examples of newly developing surface-modified lipid-based nanocarrier systems from the available literature, along with their applications, have been compiled in this work.

Citing Articles

Lipid-based nanoformulations in onychomycosis therapy: addressing challenges of current therapies and advancing treatment.

Prajapati S, Jain A, Bajpai M RSC Adv. 2025; 15(10):7799-7825.

PMID: 40070389 PMC: 11895809. DOI: 10.1039/d5ra00387c.


Revolutionizing Cancer Immunotherapy: Emerging Nanotechnology-Driven Drug Delivery Systems for Enhanced Therapeutic Efficacy.

Theivendren P, Kunjiappan S, Pavadai P, Ravi K, Murugavel A, Dayalan A ACS Meas Sci Au. 2025; 5(1):31-55.

PMID: 39991031 PMC: 11843507. DOI: 10.1021/acsmeasuresciau.4c00062.


Navigating liver cancer: Precision targeting for enhanced treatment outcomes.

Jain A, Mishra A, Hurkat P, Shilpi S, Mody N, Jain S Drug Deliv Transl Res. 2025; .

PMID: 39847205 DOI: 10.1007/s13346-024-01780-x.


Present and future of cancer nano-immunotherapy: opportunities, obstacles and challenges.

Wang M, Yu F, Zhang Y Mol Cancer. 2025; 24(1):26.

PMID: 39827147 PMC: 11748575. DOI: 10.1186/s12943-024-02214-5.


Macrophages co-loaded with drug-associated and superparamagnetic nanoparticles for triggered drug release by alternating magnetic fields.

Desai O, Kumar S, Koster M, Ullah S, Sarker S, Hagemann V Drug Deliv Transl Res. 2025; .

PMID: 39804440 DOI: 10.1007/s13346-024-01774-9.


References
1.
Rapalli V, Mahmood A, Waghule T, Gorantla S, Dubey S, Alexander A . Revisiting techniques to evaluate drug permeation through skin. Expert Opin Drug Deliv. 2021; 18(12):1829-1842. DOI: 10.1080/17425247.2021.2010702. View

2.
Li J, Xu H, Ke X, Tian J . The anti-tumor performance of docetaxel liposomes surface-modified with glycyrrhetinic acid. J Drug Target. 2012; 20(5):467-73. DOI: 10.3109/1061186X.2012.685475. View

3.
Grabarnick Portnoy E, Andriyanov A, Han H, Eyal S, Barenholz Y . PEGylated Liposomes Remotely Loaded with the Combination of Doxorubicin, Quinine, and Indocyanine Green Enable Successful Treatment of Multidrug-Resistant Tumors. Pharmaceutics. 2021; 13(12). PMC: 8708987. DOI: 10.3390/pharmaceutics13122181. View

4.
Guo C, Wang J, Cao F, Lee R, Zhai G . Lyotropic liquid crystal systems in drug delivery. Drug Discov Today. 2010; 15(23-24):1032-40. DOI: 10.1016/j.drudis.2010.09.006. View

5.
Liu Z, Yu L, Gu P, Bo R, Xu S, Wusiman A . Surface-Engineered Cubosomes Serve as a Novel Vaccine Adjuvant to Modulate Innate Immunity and Improve Adaptive Immunity in vivo. Int J Nanomedicine. 2020; 15:8595-8608. PMC: 7650836. DOI: 10.2147/IJN.S266165. View